Arcus Biosciences, Inc.
https://www.arcusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arcus Biosciences, Inc.
Gilead’s TIGIT Program Perks Up After Lung Cancer Letdown
The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.
Roche’s Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug
An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.
Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data
The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.
Gilead’s Trodelvy May Have Safety Edge Due To Lack Of Concerning Lung Toxicity
Executives said there had been no cases of interstitial lung disease, while ILD – including fatal events – has become a potential problem for AstraZeneca/Daiichi Sankyo’s dato-DXd.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice